DrugPatentWatch Database Preview
Glaxo Grp Ltd Company Profile
What is the competitive landscape for GLAXO GRP LTD, and what generic alternatives to GLAXO GRP LTD drugs are available?
GLAXO GRP LTD has eight approved drugs.
There are nineteen US patents protecting GLAXO GRP LTD drugs.
There are four hundred and eighty-eight patent family members on GLAXO GRP LTD drugs in forty-nine countries and thirty-four supplementary protection certificates in sixteen countries.
Summary for Glaxo Grp Ltd
| International Patents: | 488 |
| US Patents: | 19 |
| Tradenames: | 13 |
| Ingredients: | 4 |
| NDAs: | 8 |
Drugs and US Patents for Glaxo Grp Ltd
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaxo Grp Ltd | FLOVENT HFA | fluticasone propionate | AEROSOL, METERED;INHALATION | 021433-003 | May 14, 2004 | RX | Yes | Yes | 7,500,444*PED | Start Trial | Y | Start Trial | |||
| Glaxo Grp Ltd | BREO ELLIPTA | fluticasone furoate; vilanterol trifenatate | POWDER;INHALATION | 204275-001 | May 10, 2013 | RX | Yes | Yes | 8,113,199 | Start Trial | Y | Start Trial | |||
| Glaxo Grp Ltd | BREO ELLIPTA | fluticasone furoate; vilanterol trifenatate | POWDER;INHALATION | 204275-002 | Apr 30, 2015 | RX | Yes | Yes | 8,511,304 | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Glaxo Grp Ltd
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Glaxo Grp Ltd | ADVAIR HFA | fluticasone propionate; salmeterol xinafoate | AEROSOL, METERED;INHALATION | 021254-003 | Jun 8, 2006 | 5,674,472*PED | Start Trial |
| Glaxo Grp Ltd | ADVAIR DISKUS 100/50 | fluticasone propionate; salmeterol xinafoate | POWDER;INHALATION | 021077-001 | Aug 24, 2000 | 7,389,775*PED | Start Trial |
| Glaxo Grp Ltd | FLOVENT HFA | fluticasone propionate | AEROSOL, METERED;INHALATION | 021433-002 | May 14, 2004 | 6,966,467*PED | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for GLAXO GRP LTD drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 150 mg | ➤ Subscribe | 2007-10-30 |
International Patents for Glaxo Grp Ltd Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Yugoslavia | 29899 | Start Trial |
| Eurasian Patent Organization | 199900495 | Start Trial |
| Hungary | 230328 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Glaxo Grp Ltd Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1425001 | 92439 | Luxembourg | Start Trial | PRODUCT NAME: VILANTEROL OU UN SEL OU UN SOLVATE DE CELUI-CI |
| 1425001 | CA 2014 00021 | Denmark | Start Trial | PRODUCT NAME: VILANTEROL ELLER ET SALT ELLER SOLVAT DERAF, HERUNDER VILANTEROL TRIFENATAT; REG. NO/DATE: EU/1/13/886/001-006 20131113 |
| 1305329 | SPC/GB08/026 | United Kingdom | Start Trial | PRODUCT NAME: FLUTICASONE FUROATE AND SOLVATES THEREOF; REGISTERED: UK EU/1/07/434/001 20080111; UK EU/1/07/434/002 20080111; UK EU/1/07/434/003 20080111 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
